- Home
- ACNB vs MREO Comparison
ACNB vs MREO Comparison
Compare ACNB & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACNB
- MREO
- Stock Information
- Founded
- ACNB 1857
- MREO 2015
- Country
- ACNB United States
- MREO United Kingdom
- Employees
- ACNB N/A
- MREO N/A
- Industry
- ACNB Major Banks
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- ACNB Finance
- MREO Health Care
- Exchange
- ACNB Nasdaq
- MREO Nasdaq
- Market Cap
- ACNB 450.1M
- MREO 438.8M
- IPO Year
- ACNB N/A
- MREO N/A
- Fundamental
- Price
- ACNB $42.46
- MREO $1.74
- Analyst Decision
- ACNB Strong Buy
- MREO Strong Buy
- Analyst Count
- ACNB 4
- MREO 5
- Target Price
- ACNB $50.00
- MREO $7.20
- AVG Volume (30 Days)
- ACNB 20.4K
- MREO 4.5M
- Earning Date
- ACNB 07-24-2025
- MREO 08-12-2025
- Dividend Yield
- ACNB 3.19%
- MREO N/A
- EPS Growth
- ACNB N/A
- MREO N/A
- EPS
- ACNB 2.69
- MREO N/A
- Revenue
- ACNB $123,053,000.00
- MREO N/A
- Revenue This Year
- ACNB $38.67
- MREO N/A
- Revenue Next Year
- ACNB $5.26
- MREO $38.38
- P/E Ratio
- ACNB $15.83
- MREO N/A
- Revenue Growth
- ACNB 15.31
- MREO N/A
- 52 Week Low
- ACNB $35.37
- MREO $1.57
- 52 Week High
- ACNB $50.72
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- ACNB 46.07
- MREO 35.60
- Support Level
- ACNB $42.05
- MREO $1.71
- Resistance Level
- ACNB $44.05
- MREO $1.83
- Average True Range (ATR)
- ACNB 0.91
- MREO 0.11
- MACD
- ACNB -0.11
- MREO -0.00
- Stochastic Oscillator
- ACNB 20.50
- MREO 53.12
About ACNB ACNB Corporation
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).